Peri-implantitis: towards a new diagnostic and therapeutic paradigm

Peri-implantitis is emerging as a major public health challenge, with a prevalence reaching 19.83% at the patient level and 9.25% at the implant level. The clinical problem is critical: our conventional tools — probing depth (PPD), bleeding on probing (BOP), and radiography — are inherently retrospective. They only reveal the pathology once irreversible bone loss has occurred, thus missing the optimal minimally invasive intervention window and promoting recurrences due to the complexity of implant surfaces.

This review synthesizes recent advances to propose a structured framework for reflection on the imbalance of the "implant-microbiota-host" triad. The objective is to map the transition from homeostasis to microbial dysbiosis, to evaluate the contribution of molecular biomarkers for early diagnosis (POCT), and to analyze the evolution of treatments, from micro-ecological modulation to tissue regeneration through engineering. The fundamental hypothesis is that the shift from a symbiotic flora to a pathogenic community of Gram-negative anaerobic bacteria constitutes the primary driver of tissue destruction, necessitating a strategy that combines rigorous microbiological control and predictable functional reconstruction.

Review methodology

This work constitutes a comprehensive review aimed at structuring current knowledge on peri-implantitis. The analytical approach is based on a paradigm shift, moving away from the traditional infectious model towards a host-microbe interaction disorder model based on dysbiosis.

The analysis is organized according to a logical framework based on four fundamental pillars:

• Etiology: Study of the transition from a symbiotic microflora to a pathogenic biofilm and the loss of homeostasis.
• Diagnosis: Evaluation of the refinement of clinical and radiographic tools, as well as the contribution of biomarkers for early diagnosis (Point-of-Care Testing).
• Therapeutic evolution: Analysis of approaches ranging from conventional mechanical debridement to micro-ecological modulation.
• Regeneration: Synthesis of functional reconstruction techniques, including guided bone regeneration (GBR) and tissue engineering.

From an epidemiological perspective, the review incorporates data from a meta-analysis of a large cohort, reporting a prevalence of the pathology of 19.83% at the patient level and 9.25% at the implant level. The study notes that these figures follow an upward trend with loading time. Although the source does not detail the specific databases consulted or the systematic selection criteria, it synthesises recent advances to define clinical and scientific guidelines.

Prevalence and dynamics of peri-implant dysbiosis

This literature review, based on a large-scale meta-analysis, highlights the clinical extent of peri-implantitis. The compiled data reveal a prevalence of 19.83% at the patient level and 9.25% at the implant level. A major finding emerges: these figures follow an upward curve proportional to the duration of implant loading.

Micro-ecological analysis shows a clear transition between health and pathology. Under physiological conditions, the peri-implant microbiota is dominated by Gram-positive cocci and bacilli, living in symbiosis with the host. Conversely, the onset of the disease is marked by dysbiosis: the flora shifts towards a pathogenic community mainly composed of Gram-negative anaerobic bacteria.

Clinically, the authors highlight the progression in two distinct phases:

• Peri-implant mucositis: Reversible inflammation limited to the soft tissues, characterized by oedema and bleeding on probing (BOP).
• Peri-implantitis: Advanced stage involving progressive and irreversible bone loss around the implant in function.

A critical point raised by the review concerns current diagnostic tools. Conventional indicators, such as pocket probing depth (PPD), bleeding on probing, and 2D radiographs, are considered inherently retrospective. They only record tissue damage that has already occurred, which often leads to a lost opportunity for early and minimally invasive interventions.

Analysis of results and clinical impact

This review highlights a major epidemiological finding: with a prevalence of 19.83% at the patient level, peri-implantitis is becoming a public health issue. The study underscores a critical limitation of our current practice: the use of retrospective clinical indicators (BOP, PPD, 2D radiography). These tools only detect the pathology once irreversible tissue damage has occurred. The emergence of point-of-care tests (POCT) and molecular biomarkers is therefore presented as a critical need to intervene during the reversible phase of mucositis.

A fundamental contribution of this work lies in the description of the biofilm as a community structured by a "competitive balance". This biological resilience, combined with the ability of bacteria to persist in the micro-roughness of the implant, explains the high recurrence rates after simple mechanical debridement. The study suggests that the therapeutic future no longer relies solely on bacterial elimination, but on micro-ecological modulation and tissue engineering.

The main limitation of this review lies in the current difficulty of translating these molecular advances and smart biomaterials into standardized clinical protocols. Although the transition toward an immunomodulation approach is promising, the long-term stability of bone reconstructions will depend on our ability to integrate these new regeneration strategies (GBR, bioactive factors) with strict microbiological control.

Conclusion: Towards integrated management

The management of peri-implantitis requires a shift from a late curative treatment model to a strategy of early interception and functional reconstruction.

Summary of advancements

This review reports a prevalence of peri-implantitis affecting 19.83% of patients, highlighting the urgency of early diagnosis. The data confirm that the pathology is driven by dysbiosis where P. gingivalis acts as a key pathogen, triggering an inflammatory cascade (IL-1β, TNF-α) that activates metalloproteinases (MMPs) responsible for irreversible tissue degradation.

In concrete terms, for the practitioner:

• Go beyond retrospective diagnosis: Probing and radiography only reveal damage already sustained; actively monitor bleeding on probing (BOP) as the primary indicator of reversible mucositis before osteolysis.
• Acknowledge the limitations of mechanical debridement: The extracellular matrix (EPS) and the implant's micro-roughness protect dormant "persistent" bacteria; conventional cleaning rarely guarantees total eradication without adjuvant microbiological or chemical modulation.
• Integrate regeneration early: Faced with the failure of non-surgical methods to stop progression, implant survival relies on a combined strategy linking surface decontamination and tissue reconstruction (GBR, bioactive factors) to restore homeostasis.

Technical lexicon of the study

SLA Surfaces (Sandblasted, Large-grit, Acid-etched): Implant surfaces with increased roughness through sandblasting and acid-etching which, according to the study, promote higher bacterial plaque accumulation compared to machined surfaces.

Microbial dysbiosis: Imbalance of the host-microbe interaction characterized by the transition from a stable symbiotic microflora to a pathogenic biofilm dominated by anaerobic Gram-negative bacteria.

GBR (Guided Bone Regeneration): Guided Bone Regeneration; therapeutic strategy using physical barriers to promote the reconstruction of supporting tissues lost following peri-implant inflammation.

Micro-ecological modulation: Emerging therapeutic strategy aimed at modifying the biofilm composition to restore homeostasis, rather than being limited to non-specific mechanical removal.

PAMPs (Pathogen-Associated Molecular Patterns): Molecular patterns (such as lipopolysaccharides) recognized by the host's TLR2 and TLR4 receptors, triggering the initial inflammatory response via the NF-κB pathway.

Retrospective indicators: A term referring to traditional clinical (PPD, BOP) and radiographic measurements which, by definition, only allow for the diagnosis of pathology once irreversible tissue damage has already occurred.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all responsibility regarding the use of this information. This document is not intended for patients or the general public.